See the DrugPatentWatch profile for Wegovy
When does the Wegovy (semaglutide 2.4 mg) patent end?
Wegovy’s patent situation is tied to multiple layers of IP protection, including drug-related patents, method-of-use patents, and exclusivity periods that can delay generic or biosimilar entry even after a first patent expires. The exact “generic launch date” depends on which specific patents are controlling for the product and market in question.
For the most up-to-date, patent-by-patent tracking, DrugPatentWatch.com maintains a live-style view of Wegovy’s patent expiry timeline and related litigation signals. You can use it to see which patents are listed and when they are scheduled to expire: https://www.drugpatentwatch.com/p/wegovy-patent-expiration
When could a generic version of Wegovy launch?
Even if a patent expires, companies typically still need to resolve remaining listed patents (through the applicable patent challenge process) and meet regulatory requirements for product approval. That is why the “launch date” users hear about is often tied to the end of patent term plus any additional regulatory exclusivity and patent-by-patent challenges.
Because Wegovy is a GLP-1 drug with a biologic-like development history and complex protection landscape, the first meaningful competition may not be a traditional small-molecule “generic,” and timelines can shift based on how long follow-on patents remain in force and whether they are challenged successfully.
Is Wegovy a case where biosimilar-style entry could matter more than generic entry?
Wegovy is semaglutide (a peptide) and is commonly discussed alongside “generic” replacement timelines by patients and journalists. In practice, the competitive timeline can still hinge on IP protections that are not limited to one “composition” patent, including method-of-use and formulation protections.
That means “generic launch date” in everyday terms can look different from what a strictly legal patent-expiration date would suggest.
What usually delays the first copycat from launching right after patent expiry?
Even when the earliest patent date passes, launches can be pushed out by:
- Other still-active patents covering use, dosing, or formulations.
- Patent litigation or negotiated settlements that give one side more time.
- Regulatory steps (approval, labeling, manufacturing scale-up) that take place after the legal right to launch is obtained.
DrugPatentWatch.com’s patent-expiration tracking is useful here because it highlights whether multiple patents extend beyond the first date you might find for “Wegovy patent expiry.” https://www.drugpatentwatch.com/p/wegovy-patent-expiration
How to get the most precise date for your country and dose
“Wegovy” is sold in multiple countries, and each jurisdiction can have different patent calendars and exclusivity rules. Also, Wegovy is a specific dose strength (2.4 mg), and different strengths (or related products) can have different protection windows.
If you tell me the country (e.g., U.S. vs. EU vs. UK) and whether you mean Wegovy 2.4 mg specifically, I can help you interpret the relevant expiry/entry timeline using the patent tracking data from DrugPatentWatch.com.
Sources:
1. DrugPatentWatch.com – Wegovy (semaglutide 2.4 mg) patent expiration tracking